1 hr. ago
Johnson & Johnson (NYSE:JNJ) has proposed a whopping $5.5 billion settlement to resolve tens of thousands of lawsuits that allege its baby powder and other talc products cause ovarian cancer. The proposed settlement could finally provide investors with the visibility they have lacked for over a decade into one of the company's largest legal liabilities.
The agreement would resolve approximately 76,000 ovarian cancer claims, but it is not yet final. It requires participation from at least 95% of eligible claimants, does not cover future lawsuits, and could ultimately cost more than the headline figure. For investors, the question is whether the benefit of removing a major legal overhang outweighs the settlement's uncertain final cost.
The talc litigation has followed Johnson & Johnson (NYSE:JNJ) for over a decade, and resolving approximately 76,000 claims would reduce the uncertainty surrounding court verdicts, appeals, and legal expenses. A large but more measurable liability may be preferable to an open-ended series of trials capable of producing unpredictable verdicts.
Johnson & Johnson (NYSE:JNJ) ended fiscal Q2 2026 with approximately $21 billion of cash and marketable securities. The company also raised its full-year guidance and is on track to surpass $100 billion in annual revenue in 2026 for the first time in its 140-year history. The proposed payment is, therefore, substantial but does not appear existential for a company of J&J's scale. In addition, the payout has a staggered structure, with the company expecting to pay up to $3 billion in 2027, followed by additional payments beginning in 2028, which may also reduce the immediate pressure on liquidity.
Furthermore, Johnson & Johnson (NYSE:JNJ) may be settling from a position of improved legal strength as a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer. The company thus does not appear to be forced into an agreement following a decisive courtroom defeat.
#billion #Legal #ovarian #approximately
The agreement would resolve approximately 76,000 ovarian cancer claims, but it is not yet final. It requires participation from at least 95% of eligible claimants, does not cover future lawsuits, and could ultimately cost more than the headline figure. For investors, the question is whether the benefit of removing a major legal overhang outweighs the settlement's uncertain final cost.
The talc litigation has followed Johnson & Johnson (NYSE:JNJ) for over a decade, and resolving approximately 76,000 claims would reduce the uncertainty surrounding court verdicts, appeals, and legal expenses. A large but more measurable liability may be preferable to an open-ended series of trials capable of producing unpredictable verdicts.
Johnson & Johnson (NYSE:JNJ) ended fiscal Q2 2026 with approximately $21 billion of cash and marketable securities. The company also raised its full-year guidance and is on track to surpass $100 billion in annual revenue in 2026 for the first time in its 140-year history. The proposed payment is, therefore, substantial but does not appear existential for a company of J&J's scale. In addition, the payout has a staggered structure, with the company expecting to pay up to $3 billion in 2027, followed by additional payments beginning in 2028, which may also reduce the immediate pressure on liquidity.
Furthermore, Johnson & Johnson (NYSE:JNJ) may be settling from a position of improved legal strength as a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer. The company thus does not appear to be forced into an agreement following a decisive courtroom defeat.
#billion #Legal #ovarian #approximately
4 days ago
Last weekend, Pierce Brosnan, 73, and his wife, Keely Shaye Smith, 62, went sightseeing in Sydney, having just celebrated their 25th wedding anniversary. Their relationship has proven to be one of Hollywood's most enduring and life-affirming love stories.
They met in 1994 when she was a journalist, two and a half years after Pierce lost his first wife, Cassandra Harris, to ovarian cancer (tragically, Cassandra's daughter Charlotte, who he adopted, died from the same disease). Pierce and Keely married in 2001 at the historic Ballintubber Abbey in Ireland and have been inseparable ever since.
The couple in Sydney last weekend having just celebrated their 25th wedding anniversary - Splash News
In a 2018 interview with Closer, Pierce said: "I had a great marriage which sadly had its own ending, and I was lucky enough to find love again. We were meant to find each other. I thank God for her every day." Continuing, "I found a great woman in Keely. Not if I searched a million times over would I find one as good." Keely is equally and openly devoted, posting heartfelt messages on social media every anniversary.
In archive pictures, a natural-not-theatrical closeness was always in evidence. They were sartorially in sync too. Still are. For a Sydney harbour boat trip and dinner, they mirrored a vibe of "quiet luxury", he in a smart jacket with black jeans and a dapper cravat, she in elegant head-to-toe beige. In short, they sport what's called "couple's style".
#keely #anniversary #last #celebrated
They met in 1994 when she was a journalist, two and a half years after Pierce lost his first wife, Cassandra Harris, to ovarian cancer (tragically, Cassandra's daughter Charlotte, who he adopted, died from the same disease). Pierce and Keely married in 2001 at the historic Ballintubber Abbey in Ireland and have been inseparable ever since.
The couple in Sydney last weekend having just celebrated their 25th wedding anniversary - Splash News
In a 2018 interview with Closer, Pierce said: "I had a great marriage which sadly had its own ending, and I was lucky enough to find love again. We were meant to find each other. I thank God for her every day." Continuing, "I found a great woman in Keely. Not if I searched a million times over would I find one as good." Keely is equally and openly devoted, posting heartfelt messages on social media every anniversary.
In archive pictures, a natural-not-theatrical closeness was always in evidence. They were sartorially in sync too. Still are. For a Sydney harbour boat trip and dinner, they mirrored a vibe of "quiet luxury", he in a smart jacket with black jeans and a dapper cravat, she in elegant head-to-toe beige. In short, they sport what's called "couple's style".
#keely #anniversary #last #celebrated
20 days ago
Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology's toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from Merck's Keytruda. It is a narrow, technical-sounding approval, but it adds up to something bigger: Agilent's diagnostics business keeps racking up new indications while competitors scramble to keep pace.
Bull Case: A Diagnostics Machine That Keeps Adding Indications
This is now the eighth CE-marked indication for the 22C3 pharmDx ****** ay in the EU, following FDA approval of a related PD-L1 test (28-8 pharmDx) for esophageal and gastric cancers just nine days earlier. Each new label doesn't require Agilent to build a new product; it just extends the reach of an ****** ay already running in labs worldwide, which is a high-margin way to grow. Agilent has also been adding inorganically, closing its acquisition of Biocare Medical in June to deepen its clinical pathology reach, the same market where this new ovarian cancer approval lives. Together, the pipeline of regulatory wins and the acquisition strategy point to a company compounding its diagnostics footprint one label at a time rather than swinging for one blockbuster product.
Bear Case: A Crowded Diagnostics Field With A Scarier Neighbor
Companion diagnostics is not Agilent's alone to win. Danaher Corporation (NYSE:DHR), through its Leica Biosystems unit, competes directly for the same pathology lab budgets and just agreed on July 14 to acquire StatLab Medical Products to strengthen its own histology and AI-pathology pipeline. Danaher's own stock cratered 14% on July 21 after it trimmed its core revenue growth outlook, even though it beat on earnings and raised its profit forecast.
#pharmdx #pathology
Bull Case: A Diagnostics Machine That Keeps Adding Indications
This is now the eighth CE-marked indication for the 22C3 pharmDx ****** ay in the EU, following FDA approval of a related PD-L1 test (28-8 pharmDx) for esophageal and gastric cancers just nine days earlier. Each new label doesn't require Agilent to build a new product; it just extends the reach of an ****** ay already running in labs worldwide, which is a high-margin way to grow. Agilent has also been adding inorganically, closing its acquisition of Biocare Medical in June to deepen its clinical pathology reach, the same market where this new ovarian cancer approval lives. Together, the pipeline of regulatory wins and the acquisition strategy point to a company compounding its diagnostics footprint one label at a time rather than swinging for one blockbuster product.
Bear Case: A Crowded Diagnostics Field With A Scarier Neighbor
Companion diagnostics is not Agilent's alone to win. Danaher Corporation (NYSE:DHR), through its Leica Biosystems unit, competes directly for the same pathology lab budgets and just agreed on July 14 to acquire StatLab Medical Products to strengthen its own histology and AI-pathology pipeline. Danaher's own stock cratered 14% on July 21 after it trimmed its core revenue growth outlook, even though it beat on earnings and raised its profit forecast.
#pharmdx #pathology
25 days ago
By Dietrich Knauth
NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help bring an end to litigation that has dogged the company for over a decade.
WHAT IS THE TALC LITIGATION ABOUT?
Tens of thousands of people have sued J&J in federal and state courts, alleging that its talc-based baby powder and other products caused ovarian cancer.
J&J has long denied the allegations, arguing that decades of scientific testing show its talc products are safe and do not cause cancer.
#thousands #alleging #caused
NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help bring an end to litigation that has dogged the company for over a decade.
WHAT IS THE TALC LITIGATION ABOUT?
Tens of thousands of people have sued J&J in federal and state courts, alleging that its talc-based baby powder and other products caused ovarian cancer.
J&J has long denied the allegations, arguing that decades of scientific testing show its talc products are safe and do not cause cancer.
#thousands #alleging #caused
27 days ago
By Dietrich Knauth
NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help bring an end to litigation that has dogged the company for over a decade.
WHAT IS THE TALC LITIGATION ABOUT?
Tens of thousands of people have sued J&J in federal and state courts, alleging that its talc-based baby powder and other products caused ovarian cancer.
J&J has long denied the allegations, arguing that decades of scientific testing show its talc products are safe and do not cause cancer.
#caused #dietrich
NEW YORK, July 29 (Reuters) - After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that could finally help bring an end to litigation that has dogged the company for over a decade.
WHAT IS THE TALC LITIGATION ABOUT?
Tens of thousands of people have sued J&J in federal and state courts, alleging that its talc-based baby powder and other products caused ovarian cancer.
J&J has long denied the allegations, arguing that decades of scientific testing show its talc products are safe and do not cause cancer.
#caused #dietrich
2 months ago
Tennis Hall of Famer Chris Evert announced Thursday that her ovarian cancer is back and that she won’t be at Wimbledon this year.
Evert, 71, is an 18-time Grand Slam singles champion and a major voice in the sport who serves as an ***** yst for ESPN. But ovarian cancer, which she was first diagnosed with in December 2021, has taken her away from the game at points in recent years.
She also missed ESPN’s 2024 Australian Open broadcast after the cancer’s recurrence in December 2023.
“I have always believed in being open and honest about my health journey,” Evert wrote in a statement she posted to social media on Thursday.
“This past weekend, after undergoing CT and PET scans, I learned that my ovarian cancer has returned. I have already undergone surgery as the first step in my treatment and recovery and will begin chemotherapy in the coming weeks.”
Evert, 71, is an 18-time Grand Slam singles champion and a major voice in the sport who serves as an ***** yst for ESPN. But ovarian cancer, which she was first diagnosed with in December 2021, has taken her away from the game at points in recent years.
She also missed ESPN’s 2024 Australian Open broadcast after the cancer’s recurrence in December 2023.
“I have always believed in being open and honest about my health journey,” Evert wrote in a statement she posted to social media on Thursday.
“This past weekend, after undergoing CT and PET scans, I learned that my ovarian cancer has returned. I have already undergone surgery as the first step in my treatment and recovery and will begin chemotherapy in the coming weeks.”
2 months ago
Chris Evert revealed her ovarian cancer has returned after an abnormal CT scan led to exploratory surgery
The tennis legend will undergo chemotherapy and step back from professional commitments to focus on her health
Evert hopes her openness about her journey raises awareness about the importance of early detection
Chris Evert revealed that she has been diagnosed with cancer for the third time.
On Thursday, June 25, the tennis legend posted on Instagram and shared that her ovarian cancer returned. The disease was detected earlier this week when the 71-year-old underwent an exploratory surgery following an abnormal CT scan.
The tennis legend will undergo chemotherapy and step back from professional commitments to focus on her health
Evert hopes her openness about her journey raises awareness about the importance of early detection
Chris Evert revealed that she has been diagnosed with cancer for the third time.
On Thursday, June 25, the tennis legend posted on Instagram and shared that her ovarian cancer returned. The disease was detected earlier this week when the 71-year-old underwent an exploratory surgery following an abnormal CT scan.
2 months ago
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street ******* ysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) 2026 conference.
Citizens said that data for three drugs in BeOne's pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer. The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer.
Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.
The firm said it arrived at the $396 price target through a discounted earnings and revenue multiple ******* ysis. It added that it has confidence in BeOne funding its ambitious pipeline because the company holds $4.85 billion in cash, carries more cash than debt, and generates gross profit margins of 88%.
BeOne Medicines AG (NASDAQ:ONC) is a commercial-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Its pipeline includes candidates designed to address unmet needs in solid tumors and hematologic malignancies.
Citizens said that data for three drugs in BeOne's pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer. The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer.
Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.
The firm said it arrived at the $396 price target through a discounted earnings and revenue multiple ******* ysis. It added that it has confidence in BeOne funding its ambitious pipeline because the company holds $4.85 billion in cash, carries more cash than debt, and generates gross profit margins of 88%.
BeOne Medicines AG (NASDAQ:ONC) is a commercial-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Its pipeline includes candidates designed to address unmet needs in solid tumors and hematologic malignancies.
3 months ago
June 4 (Reuters) - The UK cost-effectiveness watchdog on Thursday recommended AbbVie's "guided missile" cancer therapy, Elahere, for patients with a hard-to-treat form of ovarian cancer.
The drug, Elahere, will be made available to patients under a confidential commercial agreement between AbbVie and the state-run National Health Service, the National Institute for Health and Care Excellence (NICE) said.
The decision comes after NICE revised its value appraisal framework as part of a broader UK-U.S. deal last year to secure zero tariffs on British pharmaceutical products and medical technology, in exchange for increased drug spending and changes to its ******* sment criteria.
The new framework would widen access to treatments previously rejected on cost grounds.
Critically ill patients whose cancer has stopped responding to standard chemotherapy will now be able to access Elahere through the NHS. The drug was previously limited to clinical trials, private care, or compassionate use.
The drug, Elahere, will be made available to patients under a confidential commercial agreement between AbbVie and the state-run National Health Service, the National Institute for Health and Care Excellence (NICE) said.
The decision comes after NICE revised its value appraisal framework as part of a broader UK-U.S. deal last year to secure zero tariffs on British pharmaceutical products and medical technology, in exchange for increased drug spending and changes to its ******* sment criteria.
The new framework would widen access to treatments previously rejected on cost grounds.
Critically ill patients whose cancer has stopped responding to standard chemotherapy will now be able to access Elahere through the NHS. The drug was previously limited to clinical trials, private care, or compassionate use.
9 months ago
We are learning more about the ovaries.
Diana Laird, PhD, a professor of obstetrics, gynecology, and reproductive sciences at UCSF, says she sought to better understand the geography and anatomy of the ovaries — the fastest-aging but least-studied organ.
More from Flow ******* e
Tossing and Turning? Latest Science Reveals the Truth About Sleep in Midlife
The faster the ovaries age, the greater the risk of chronic conditions and earlier mortality, Laird says. Slowing ovarian aging doesn’t just prolong the fertility window; it may also play a significant role in how well women age.
https:
Diana Laird, PhD, a professor of obstetrics, gynecology, and reproductive sciences at UCSF, says she sought to better understand the geography and anatomy of the ovaries — the fastest-aging but least-studied organ.
More from Flow ******* e
Tossing and Turning? Latest Science Reveals the Truth About Sleep in Midlife
The faster the ovaries age, the greater the risk of chronic conditions and earlier mortality, Laird says. Slowing ovarian aging doesn’t just prolong the fertility window; it may also play a significant role in how well women age.
https:
